Phase II trial of dexverapamil and epirubicin in patients with non-responsive metastatic breast cancer
M. Lehnert(Merck & Co., Inc., Rahway, NJ, USA (United States)), H. Küpper, B. Thuerlimann(Universität Hamburg), N. Kroeger(Kantonsspital St. Gallen), J. Schueller(Universität Hamburg), K. Mross
Cited by 32
Related Papers
Phase I Study of Pembrolizumab (MK-3475; Anti–PD-1 Monoclonal Antibody) in Patients with Advanced Solid Tumors
|Clinical Cancer Research|2015|799
Methods to detect P-glycoprotein-associated multidrug resistance in patients' tumors: consensus recommendations.
|PubMed|1996|388
Phase I Clinical Study of AZD2171, an Oral Vascular Endothelial Growth Factor Signaling Inhibitor, in Patients With Advanced Solid Tumors
|Journal of Clinical Oncology|2007|303